NasdaqCM:HYMC
NasdaqCM:HYMCMetals and Mining

Hycroft Mining (HYMC) Valuation After High-Grade Silver Discoveries and Strong 2025–2026 Drill Program Results

Hycroft Mining Holding (HYMC) just dropped a detailed update on its 2025 to 2026 exploration program in Nevada, with new high grade silver hits at Vortex and Brimstone that could reshape future mine plans. See our latest analysis for Hycroft Mining Holding. The market has taken notice, with Hycroft Mining Holding’s share price returning 155.42 percent over the past month and a huge 975.44 percent year to date. The one year total shareholder return of 1107.88 percent shows momentum has sharply...
NYSE:SCI
NYSE:SCIConsumer Services

Service Corporation International (SCI): Reassessing Valuation After Weak Volumes, Cash Flows and Returns on Capital

Service Corporation International (SCI) is back in focus after fresh data underscored two years of disappointing funeral service volumes, weak free cash flow, and falling returns on capital, all of which pressure its ability to fund growth or support shareholder payouts. See our latest analysis for Service Corporation International. Despite these operational headwinds, SCI's share price has held at about $78.73, with a modest year to date share price return. Its five year total shareholder...
TSE:9983
TSE:9983Specialty Retail

How Investors Are Reacting To Fast Retailing (TSE:9983) Raising Graduate Pay and Management Equity Incentives

Fast Retailing recently announced that from March it raised base annual pay for new graduates in Japan, lifting globally mobile management trainee salaries by about 12% to ¥5.9 million and other new graduate roles by about 10% to ¥4.5 million, alongside fresh stock-based incentives for senior management. This pay and equity package signals a stronger emphasis on talent attraction, retention, and management-shareholder alignment as the company pursues global expansion and productivity...
NasdaqGS:OLMA
NasdaqGS:OLMABiotechs

Olema Pharmaceuticals (OLMA): Reassessing Valuation After S&P Biotechnology Select Industry Index Inclusion

Olema Pharmaceuticals (OLMA) just earned a spot in the S&P Biotechnology Select Industry Index, a milestone that can quietly reshape its shareholder base as index funds and biotech-focused investors take a closer look. See our latest analysis for Olema Pharmaceuticals. That index inclusion caps a wild run for Olema, with the share price at $28.18 after a 30 day share price return of 21.62 percent and a 90 day surge of 220.59 percent. The 1 year total shareholder return of 347.30 percent hints...
NYSE:PAR
NYSE:PARSoftware

Smart Passes Wallet-Native Loyalty Launch Might Change The Case For Investing In PAR Technology (PAR)

In December 2025, PAR Technology Corporation launched Smart Passes, a wallet-native loyalty solution within its PAR Punchh platform that lets restaurant brands deliver real-time, app-free rewards and offers through Apple and Google Wallet on guests’ mobile phones. This move positions PAR to deepen its role in restaurant guest engagement by integrating loyalty directly into everyday mobile behavior, potentially enhancing the appeal and revenue opportunity of its broader cloud platform for...
NasdaqGS:ALNY
NasdaqGS:ALNYBiotechs

Alnylam Pharmaceuticals (ALNY) Valuation Check After NASDAQ-100 Entry and $250m Manufacturing Expansion

Alnylam Pharmaceuticals (ALNY) just earned a spot in the NASDAQ 100, a move that can channel more passive money into the stock and highlights how far the RNAi pioneer has come with investors. See our latest analysis for Alnylam Pharmaceuticals. The NASDAQ 100 inclusion caps a strong run, with the share price up sharply year to date and a five year total shareholder return above 200 percent, as investors reward recent R and D progress and the 250 million dollar manufacturing expansion. If...
NasdaqGM:ATAI
NasdaqGM:ATAIPharmaceuticals

Assessing Atai Beckley (NasdaqGM:ATAI) Valuation After NASDAQ Biotechnology Index Inclusion

Atai Beckley (NasdaqGM:ATAI) just earned a spot in the NASDAQ Biotechnology Index, a move that often draws in fresh institutional money as index funds rebalance and passive strategies update their biotech exposure. See our latest analysis for Atai Beckley. The inclusion in the NASDAQ Biotechnology Index caps a volatile stretch, with a 30 day share price return of 13.16 percent but a 90 day share price return still down 23.35 percent. At the same time, the year to date share price return of...
NYSE:VICI
NYSE:VICISpecialized REITs

Will Tenant Jitters and New Gaming Deals Change VICI Properties' (VICI) Experiential Real Estate Narrative?

In recent weeks, VICI Properties has faced analyst downgrades tied to concerns over tenant stability and a regional gaming lease with Caesars Entertainment, even as it moves to diversify by adding Clairvest as a tenant and acquiring the operations of MGM Northfield Park in Ohio, a deal expected to close in the first half of 2026. This combination of tenant risk questions and expansion into non-core gaming assets highlights how VICI’s evolving portfolio could reshape its risk profile and...
NasdaqGM:GPCR
NasdaqGM:GPCRPharmaceuticals

Structure Therapeutics (GPCR): Is a 5x Price-to-Book Multiple Fair After the Recent Share Price Surge?

Structure Therapeutics (GPCR) has quietly turned heads after its stock climbed roughly 84% over the past month and more than doubled in the past 3 months, despite ongoing losses and zero reported revenue. See our latest analysis for Structure Therapeutics. That surge has come after a year of choppy trading, with the latest 1 day and 7 day share price returns in the red, even as the 30 day and year to date share price returns point to strong, building momentum from a base of clinical stage...
NasdaqGS:ULCC
NasdaqGS:ULCCAirlines

Frontier (ULCC): Evaluating the Airline’s Valuation Following Its Recent CEO Transition

Frontier Group Holdings (ULCC) is back on investors radar after naming President James G. Dempsey as Interim CEO, stepping in for longtime chief Barry L. Biffle, who shifts to an advisory role. See our latest analysis for Frontier Group Holdings. The leadership shake up lands as the share price sits at $5.06, with a strong 1 month share price return of 33.51 percent but a much weaker 1 year total shareholder return of negative 28.93 percent. This suggests short term momentum is building even...
NasdaqGS:ZG
NasdaqGS:ZGReal Estate

Zillow (ZG) Valuation Check After Recent 3‑Month Share Price Weakness

Zillow Group (ZG) has quietly drifted lower over the past 3 months, even as annual revenue and net income growth stay solidly positive. That disconnect is what makes the stock interesting now. See our latest analysis for Zillow Group. Over the past year, Zillow Group’s 1 year total shareholder return of negative 7.39 percent and 90 day share price return of negative 11.12 percent suggest momentum has cooled. However, its 3 year total shareholder return of 111.58 percent shows the longer term...
NasdaqGS:PHVS
NasdaqGS:PHVSPharmaceuticals

Why Pharvaris (PHVS) Is Up 13.3% After RAPIDe-3 Success And 2026 Deucrictibant Filing Plans

Earlier this week, Pharvaris reported positive top-line results from its pivotal RAPIDe-3 trial of deucrictibant for on-demand treatment of hereditary angioedema attacks, meeting the primary endpoint with significantly faster symptom relief versus placebo. The company also confirmed plans to begin filing marketing authorization applications for deucrictibant in the first half of 2026, signaling a transition from late-stage development toward potential commercialization in this rare disease...
NYSE:BXP
NYSE:BXPOffice REITs

How BXP’s Dividend, CEO Extension and New Incentive Plan Will Impact BXP (BXP) Investors

BXP, Inc. recently declared a regular quarterly cash dividend of US$0.70 per share for the October–December 2025 period, payable on January 29, 2026, and also extended CEO Owen D. Thomas’s employment agreement through 2029 while approving a multi-year equity-based Outperformance Plan tied to long-term share performance. Together with recent asset recycling moves and a large pre-leased development in Washington, DC, these actions highlight BXP’s focus on leadership stability, capital...
NasdaqGM:IRON
NasdaqGM:IRONBiotechs

Disc Medicine (IRON) Is Down 13.5% After FDA Scrutiny Clouds Bitopertin Pathway And Insider Sales - What's Changed

In recent days, Disc Medicine has come under pressure as questions from an FDA official and media reports cast doubt on the efficacy and accelerated review pathway of its lead EPP candidate, bitopertin, while insider share sales added to investor unease. Despite this scrutiny, Disc and several covering analysts report that FDA interactions remain collaborative, with current inquiries framed as procedural clarifications rather than formal challenges to bitopertin’s clinical benefit. We’ll now...
XTRA:MUV2
XTRA:MUV2Insurance

Munich Re (XTRA:MUV2): Revisiting Valuation After New 2026 Profit and Revenue Targets

Münchener Rückversicherungs-Gesellschaft in München (XTRA:MUV2) has just laid out its 2026 roadmap, targeting IFRS net profit of €6.3 billion, €64 billion in insurance revenue, and a return on investment above 3.5%. See our latest analysis for Münchener Rückversicherungs-Gesellschaft in München. The upbeat 2026 roadmap lands after a steady run, with the share price at €560.6 and a roughly mid teens year to date share price return alongside a strong three year total shareholder return well...
NasdaqGS:VIAV
NasdaqGS:VIAVCommunications

Viavi Solutions (VIAV): Assessing Valuation After Growth Wins in High-Speed Optics, Defense and Quantum Security

Viavi Solutions (VIAV) is back in the spotlight after a cluster of growth signals, including an outperforming Inertial Labs acquisition, a new federal timing contract, and a quantum security partnership. See our latest analysis for Viavi Solutions. Those growth moves seem to be landing with investors, with the share price at $18.41 and a powerful 90 day share price return of 48.35 percent feeding into an 82.28 percent year to date share price gain and a 79.43 percent one year total...
NYSE:DXC
NYSE:DXCIT

Is DXC’s New AdvisoryX AI Execution Group Altering The Investment Case For DXC Technology (DXC)?

In December 2025, DXC Technology launched AdvisoryX, a global advisory and consulting group that combines strategic, operational, and technology expertise to help enterprises close the gap between AI ambition and real-world execution. By pairing consulting-led engagements with an engineering backbone and integrated AI lifecycle solutions, DXC is positioning AdvisoryX as a way for companies to move beyond AI pilots and pressure-driven adoption toward governed, scalable deployments that can...
NYSE:MLM
NYSE:MLMBasic Materials

Will Extending Its US$800 Million Credit Facility to 2030 Change Martin Marietta’s (MLM) Narrative?

On December 19, 2025, Martin Marietta Materials, Inc. amended its US$800,000,000 five-year senior unsecured revolving credit facility, extending the maturity date of borrowings under the agreement to December 21, 2030. This extension strengthens the company’s access to committed bank liquidity, offering greater visibility over funding for future capital needs and operations. Next, we’ll explore how locking in this revolving credit facility through 2030 may influence Martin Marietta’s...
ADX:SCIDC
ADX:SCIDCBasic Materials

Middle Eastern Penny Stocks To Watch In December 2025

Most Gulf markets have recently experienced an upswing, buoyed by rising oil prices and optimism surrounding potential U.S. Federal Reserve rate cuts. In this context, penny stocks—often representing smaller or emerging companies—remain a relevant investment area for those seeking growth opportunities. Despite their historical connotations, these stocks can offer a blend of affordability and potential when backed by strong financial health, making them worth considering for investors...
TASE:ARD
TASE:ARDElectronic

Undiscovered Gems In Middle East Stocks For December 2025

As the Gulf markets continue to rise, buoyed by increasing oil prices and optimism around potential U.S. Federal Reserve rate cuts, investors are keeping a keen eye on the opportunities within this dynamic region. In such an environment, identifying stocks with solid fundamentals and growth potential can be key to navigating the evolving economic landscape, making it essential for investors to stay informed about emerging prospects in Middle Eastern markets.